文献速递前列腺癌

新冠疫情期间英格兰漏诊两万例前列腺癌

During the COVID-19 pandemic 20 000 prostate cancer diagnoses were missed in England.
PubMed 文献 · BJU Int · 2024-02-27

疫情期间诊断年龄向高龄偏移,2023年发病率回升不足以弥补漏诊病例,估计全英格兰漏诊约2万例。

要点

  • 2020年前列腺癌记录发病率较预期下降4772例(31%),2021年下降3148例(18%)。
  • 疫情期间诊断年龄向高龄偏移,2020年平均71.6岁、2021年71.8岁,2019年为71.3岁。
  • 2023年发病率回升不足以弥补漏诊病例,估计全英格兰漏诊约2万例。

核心结论

  • 按数据集覆盖40%人口推算,疫情仅英格兰即导致约2万例前列腺癌漏诊。
  • 2023年记录发病率的回升不足以弥补漏诊病例,疫情期间前列腺癌患病率持续低于预期。
  • 作者认为随着恢复工作继续,医疗应聚焦于找到受影响的男性;研究应聚焦于调查高龄诊断男性的潜在危害。

研究设计与样本

  • 展示2015年1月至2023年7月每10万成年男性每月前列腺癌发病率、患病率和死亡率。
  • 使用广义线性模型和疫情前数据预测自2020年3月起若未发生疫情的预期率,以预测值95%CI评估预测与观察率的差异显著性。

主要发现

  • 2020年记录发病率下降4772例(31%)(15550 vs 20322;95%CI 19241-21403)。
  • 2021年发病率开始恢复,下降3148例(18%)(17950 vs 21098;95%CI 19740-22456)。
  • 至2022年发病率恢复至预期水平。
  • 疫情期间诊断年龄向高龄偏移:2020年平均71.6岁(95%CI 71.5-71.8),2021年71.8岁(95%CI 71.7-72.0),2019年为71.3岁(95%CI 71.1-71.4)。
  • 疫情期间前列腺癌患病率持续低于预期。

临床怎么用

  • 作者认为随着恢复工作继续,医疗应聚焦于找到受疫情影响的男性。
  • 作者认为研究应聚焦于调查高龄诊断男性的潜在危害。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To investigate the effect of the COVID-19 pandemic on prostate cancer incidence, prevalence, and mortality in England. PATIENTS AND METHODS: With the approval of NHS England and using the OpenSAFELY-TPP dataset of 24 million patients, we undertook a cohort study of men diagnosed with prostate cancer. We visualised monthly rates in prostate cancer incidence, prevalence, and mortality per 100 000 adult men from January 2015 to July 2023. To assess the effect of the pandemic, we used generalised linear models and the pre-pandemic data to predict the expected rates from March 2020 as if the pandemic had not occurred. The 95% confidence intervals (CIs) of the predicted values were used to estimate the significance of the difference between the predicted and observed rates. RESULTS: In 2020, there was a drop in recorded incidence by 4772 (31%) cases (15 550 vs 20 322; 95% CI 19 241-21 403). In 2021, the incidence started to recover, and the drop was 3148 cases (18%, 17 950 vs 21 098; 95% CI 19 740-22 456). By 2022, the incidence returned to the levels that would be expected. During the pandemic, the age at diagnosis shifted towards older men. In 2020, the average age was 71.6 (95% CI 71.5-71.8) years, in 2021 it was 71.8 (95% CI 71.7-72.0) years as compared to 71.3 (95% CI 71.1-71.4) years in 2019. CONCLUSIONS: Given that our dataset represents 40% of the population, we estimate that proportionally the pandemic led to 20 000 missed prostate cancer diagnoses in England alone. The increase in incidence recorded in 2023 was not enough to account for the missed cases. The prevalence of prostate cancer remained lower throughout the pandemic than expected. As the recovery efforts continue, healthcare should focus on finding the men who were affected. The research should focus on investigating the potential harms to men diagnosed at older age.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Lemanska A, Andrews C, Fisher L, et al. During the COVID-19 pandemic 20 000 prostate cancer diagnoses were missed in England. BJU Int. 2024. PMID: 38414224. doi:10.1111/bju.16305

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。